John G. Ullman & Associates’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,530
Closed -$211K 184
2025
Q4
$211K Sell
1,530
-1,450
-49% -$190K 0.03% 173
2025
Q3
$382K Sell
2,980
-134,427
-98% -$16.4M 0.05% 139
2025
Q2
$16.6M Sell
137,407
-716
-0.5% -$80.7K 2.47% 9
2025
Q1
$15.4M Sell
138,123
-1,267
-0.9% -$135K 2.37% 7
2024
Q4
$13.6M Sell
139,390
-2,076
-1% -$221K 2% 10
2024
Q3
$16.3M Sell
141,466
-35,782
-20% -$4.06M 2.34% 9
2024
Q2
$18.9M Sell
177,248
-1,939
-1% -$195K 2.88% 6
2024
Q1
$17.3M Sell
179,187
-1,713
-0.9% -$176K 2.66% 8
2023
Q4
$18.3M Sell
180,900
-1,790
-1% -$173K 2.9% 7
2023
Q3
$18.6M Sell
182,690
-2,245
-1% -$228K 3.04% 8
2023
Q2
$18.7M Sell
184,935
-3,110
-2% -$311K 2.88% 7
2023
Q1
$17.3M Sell
188,045
-6,166
-3% -$539K 2.69% 7
2022
Q4
$17.6M Sell
194,211
-3,683
-2% -$310K 2.81% 9
2022
Q3
$15M Buy
197,894
+9,180
+5% +$761K 2.63% 9
2022
Q2
$16M Buy
188,714
+2,295
+1% +$201K 2.56% 10
2022
Q1
$16.4M Buy
186,419
+8,180
+5% +$708K 2.27% 10
2021
Q4
$15.6M Buy
178,239
+3,285
+2% +$273K 2.14% 12
2021
Q3
$14.3M Sell
174,954
-180
-0.1% -$16.2K 1.95% 16
2021
Q2
$16M Sell
175,134
-2,330
-1% -$207K 2.08% 16
2021
Q1
$15.2M Buy
177,464
+7,031
+4% +$631K 2.04% 17
2020
Q4
$16.1M Buy
170,433
+18,948
+13% +$1.66M 2.49% 9
2020
Q3
$13.2M Sell
151,485
-1,000
-0.7% -$86.6K 2.73% 9
2020
Q2
$13.3M Sell
152,485
-350
-0.2% -$30.2K 3.25% 7
2020
Q1
$12.6M Sell
152,835
-2,515
-2% -$224K 3.34% 7
2019
Q4
$14.7M Sell
155,350
-2,775
-2% -$249K 2.53% 7
2019
Q3
$13.7M Sell
158,125
-675
-0.4% -$60.6K 2.5% 8
2019
Q2
$14.5M Sell
158,800
-19,063
-11% -$1.61M 2.55% 8
2019
Q1
$15.3M Sell
177,863
-2,734
-2% -$219K 2.77% 7
2018
Q4
$13.9M Sell
180,597
-762
-0.4% -$59.3K 2.8% 8
2018
Q3
$14M Sell
181,359
-234
-0.1% -$17.3K 2.55% 8
2018
Q2
$12.3M Buy
181,593
+2,985
+2% +$206K 2.32% 10
2018
Q1
$12.9M Buy
178,608
+1,869
+1% +$142K 2.5% 10
2017
Q4
$13.3M Buy
176,739
+288
+0.2% +$21.7K 2.65% 9
2017
Q3
$13.6M Buy
176,451
+45,444
+35% +$3.43M 2.65% 9
2017
Q2
$9.8M Buy
131,007
+4,313
+3% +$306K 1.94% 13
2017
Q1
$8.43M Buy
126,694
+9,554
+8% +$637K 1.74% 15
2016
Q4
$7.65M Buy
117,140
+57,229
+96% +$3.71M 1.6% 19
2016
Q3
$4.24M Buy
59,911
+6,288
+12% +$458K 0.87% 41
2016
Q2
$3.96M Sell
53,623
-613
-1% -$42.4K 0.81% 44
2016
Q1
$3.52M Sell
54,236
-2,577
-5% -$175K 0.83% 39
2015
Q4
$4.38M Sell
56,813
-1,636
-3% -$130K 0.97% 31
2015
Q3
$4.81M Sell
58,449
-4,554
-7% -$405K 1.14% 29
2015
Q2
$5.55M Sell
63,003
-4,503
-7% -$413K 1.05% 28
2015
Q1
$5.96M Sell
67,506
-1,361
-2% -$121K 1.13% 24
2014
Q4
$5.72M Sell
68,867
-1,507
-2% -$125K 1.08% 26
2014
Q3
$5.94M Sell
70,374
-19,173
-21% -$1.55M 1.14% 25
2014
Q2
$7.26M Sell
89,547
-1,674
-2% -$132K 1.33% 24
2014
Q1
$6.95M Sell
91,221
-4,531
-5% -$330K 1.29% 24
2013
Q4
$6.9M Sell
95,752
-3,180
-3% -$221K 1.32% 23
2013
Q3
$6.8M Sell
98,932
-13,550
-12% -$896K 1.38% 24
2013
Q2
$7.13M Buy
+112,482
New +$7.32M 1.49% 21

Other funds holding NVS

John G. Ullman & Associates's NVS Position: Q1 2026 in Review

John G. Ullman & Associates sold out of Novartis (NVS) in Q1 2026, closing a stake of 1,530 shares — an estimated $211K sold.

John G. Ullman & Associates first reported a position in NVS in Q2 2013 and held it in 51 quarters. The position peaked at $18.9M in Q2 2024. 1,599 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • John G. Ullman & Associates reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
  • John G. Ullman & Associates sold 1,530 Novartis shares in Q1 2026, an estimated $211K.
  • John G. Ullman & Associates first reported a position in Novartis in Q2 2013 and held it in 51 quarters.
  • John G. Ullman & Associates's Novartis position peaked at $18.9M in Q2 2024.
  • 1,599 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on John G. Ullman & Associates's 13F filing for Q1 2026, filed 6 May 2026.